BBB-nonpermeable SIGMAR1 agonists MY33-1/2 treat Timothy Syndrome, reducing cardiac arrhythmias via targeted stem-cell model rescue.

PDE5 inhibitors with a novel benzonaphthyridine scaffold cross the blood-brain barrier to enhance memory, aiding Alzheimer’s therapy.

Engineered probiotics produce E-cadherin peptides to block Fn attachment, lowering Fusobacterium virulence and colonization.

Nanofibrous scaffold locally releases ACHP to inhibit NF-kB, enabling targeted immunomodulation with reduced systemic effects.

Non-hallucinogenic serotonin 2A agonist Ariadne targets Parkinson’s and psychiatric disorders, offering safer, broader therapeutic potential.

Small-molecule protein therapy boosts cardiac contractility by raising calcium without increasing heart rate, reducing tachycardia risk.

Ubiquinone-based anesthetic with safe, controllable, reversible sedation; minimal side effects, suitable for diverse patient groups.

Retinoid pathway inverse agonists reprogram ACC cells to non-tumorigenic states, enabling targeted differentiation and death.

LCAT-activating lipids aim to restore brain lipid metabolism, potentially slowing neurodegeneration and offering broad neurological disease applications.

SSRI-based MMP-1 inhibition slows COPD progression; oral/inhaled delivery reduces cigarette-smoke–driven lung damage and inflammation.

Combines epigenetic inhibitors with anti-androgens to reverse NEPC differentiation and improve treatment response.

Four small molecules block ID2/VHL, promote HIF degradation, potentially slowing tumor growth and angiogenesis in cancers.

A multi-target Alzheimer's drug discovery platform delivering preclinical lead compounds with rapid in vivo and in vitro validation.

Metabolic reprogramming to boost cellular anabolism, slowing neurodegeneration by targeted glycolytic pathway manipulation.

A novel immunosuppressant blocks T cell expansion to treat organ transplant rejection and autoimmune/inflammatory diseases.